One in ten emergency patients with visible blood in their urine die within three months of presenting at A&E, new research has found. The WASHOUT study, presented at the European Association of Urology Congress (EAU26) in London, found that a scan within 48 hours could reduce this risk.

Engineers at Duke University have demonstrated a technique that uses microbubbles and ultrasound to help relatively large cancer drugs enter tumor cells and cause them to self-destruct.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published today in Science Advances, describe a manufacturing approach that, compared to the existing process, generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection in mouse models.

CD4⁺ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and immune resistance.

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular "bottlenecks" that have limited the natural production of this drug for over 50 years.